-
1
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
2
-
-
84863116743
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
-
Sosman JA, Kim KB, Schuchter L, et al,. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
-
(2012)
N Engl J Med
, vol.366
, pp. 707-714
-
-
Sosman, J.A.1
Kim, K.B.2
Schuchter, L.3
-
3
-
-
10244236377
-
Acute renal failure - Definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group
-
Bellomo R, Ronco C, Kellum JA, et al,. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-12.
-
(2004)
Crit Care
, vol.8
-
-
Bellomo, R.1
Ronco, C.2
Kellum, J.A.3
-
4
-
-
77955895112
-
Acute interstitial nephritis
-
Praga M, González E,. Acute interstitial nephritis. Kidney Int 2010; 77: 956-61.
-
(2010)
Kidney Int
, vol.77
, pp. 956-961
-
-
Praga, M.1
González, E.2
-
5
-
-
77956513286
-
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
-
Bollag G, Hirth P, Tsal J, et al,. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-9.
-
(2010)
Nature
, vol.467
, pp. 596-599
-
-
Bollag, G.1
Hirth, P.2
Tsal, J.3
-
6
-
-
77954376912
-
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
-
Yang H, Higgins B, Kolinsky K, et al,. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010; 70: 5518-27.
-
(2010)
Cancer Res
, vol.70
, pp. 5518-5527
-
-
Yang, H.1
Higgins, B.2
Kolinsky, K.3
-
7
-
-
70350683587
-
Acute kidney injury in patients with inactive cytochrome P450 polymorphisms
-
Leung N, Eirin A, Irazabal MV, et al,. Acute kidney injury in patients with inactive cytochrome P450 polymorphisms. Ren Fail 2009; 31: 749-52.
-
(2009)
Ren Fail
, vol.31
, pp. 749-752
-
-
Leung, N.1
Eirin, A.2
Irazabal, M.V.3
-
8
-
-
0030338073
-
Anti-cytochrome P450 autoantibodies in drug-induced disease
-
Beaune P,. Anti-cytochrome P450 autoantibodies in drug-induced disease. Eur J Haematol Suppl 1996; 60: 89-92.
-
(1996)
Eur J Haematol Suppl
, vol.60
, pp. 89-92
-
-
Beaune, P.1
-
9
-
-
84868120907
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial
-
Long GV, Trefzer U, Davies MA, et al,. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 1087-95.
-
(2012)
Lancet Oncol
, vol.13
, pp. 1087-1095
-
-
Long, G.V.1
Trefzer, U.2
Davies, M.A.3
-
10
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
-
Hauschild A, Grob J-J, Demidov LV, et al,. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.-J.2
Demidov, L.V.3
-
11
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B, Eisen T, Stadler WM, et al,. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
12
-
-
77949326926
-
Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib
-
Overkleeft ENM, Goldschmeding R, van Reekum F, et al,. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol 2010; 21: 184-5.
-
(2010)
Ann Oncol
, vol.21
, pp. 184-185
-
-
Overkleeft, E.N.M.1
Goldschmeding, R.2
Van Reekum, F.3
|